[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651302":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":20,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"New Valley University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Antiphospholipid syndrome patients","EXPERIMENTAL","* Definite APS by Sydney criteria (thrombotic and\u002For obstetric) with persistent aPL positivity.\n* ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)",[13],"Diagnostic Test: Platelet count",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Platelet count","Longitudinal platelet counts (routine visits, hospitalizations) will be extracted.\n\n• Using group based trajectory modeling or latent class mixed models, patients will be assigned to data driven platelet trajectory classes, anticipated as:\n\n1. Stable normal (no thrombocytopenia)\n2. Transient thrombocytopenia (recovery to normal)\n3. Intermittent\u002Ffluctuating thrombocytopenia\n4. Persistent mild-moderate thrombocytopenia (e.g., 50-149×10⁹\u002FL)\n5. Persistent severe thrombocytopenia (\\\u003C50×10⁹\u002FL)",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Asmaa N Hussein, MD","CONTACT","01065161752","asmaanady_1010@med.nvu.edu.eg",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Al Khārjah","Kharga Oasis","72511","Egypt","EG",{"type":36,"coordinates":37},"Point",[38,39],30.54653,25.45101,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Asmaa Nady Hussein","Lecturer of Internal Medicine","100651302","thrombocytopenia-trajectories-in-antiphospholipid-syndrome-a-multicenter-cohort-study-100651302",false,"NCT07757789","Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study","Thrombocytopenia Trajectories as a Dynamic Biomarker of Clinical Severity and Survival in Antiphospholipid Syndrome: A Multicenter Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years.\n* Definite APS by Sydney criteria (thrombotic and\u002For obstetric) with persistent aPL positivity.\n* ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)\n\nExclusion Criteria:\n\n* Thrombocytopenia clearly attributable to non APS causes (e.g., chemotherapy, myelodysplastic syndromes, cirrhosis, HIV).\n* Concomitant conditions strongly affecting survival independent of APS (e.g., metastatic cancer), at investigator discretion","ALL","18 Years",{"count":57,"type":58},200,"ESTIMATED","INTERVENTIONAL",[61],"NA","Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR\u002FEULAR APS criteria as an important non criteria\u002Fhematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.",[64],"Antiphospholipid Syndrome",[66],"thrombocytopenia","2026-08-05",{"date":69,"type":70},"2026-08-11","ACTUAL",{"date":72,"type":70},"2026-07-01",{"date":74,"type":58},"2027-12-31",{"name":5,"class":6},1]